Literature DB >> 25893414

A Contemporary Analysis of Surgical Trends in the Treatment of Squamous Cell Carcinoma of the Oropharynx from 1998 to 2012: A Report from the National Cancer Database.

Erik Liederbach1, Carol M Lewis2, Katharine Yao1,3, Bruce E Brockstein3,4, Chi-Hsiung Wang5, Waseem Lutfi1, Mihir K Bhayani6,7.   

Abstract

BACKGROUND: This study examined surgical trends for oropharynx squamous cell carcinoma (OPC) from 1998 to 2012, with a post-2009 focus coinciding with the Food and Drug Administration (FDA) approval of transoral robotic surgery (TORS).
METHODS: Using the National Cancer Data Base, the study analyzed 84,449 patients with stage I-IVB OPC. χ (2) tests and logistic regression models were used to examine surgical trends.
RESULTS: The use of surgery decreased from 41.4 % in 1998 to 30.4 % in 2009 (p < 0.001). The surgical trends reversed and in 2012 increased to 34.8 % (p < 0.001). There was much variation in surgery in 2012 between American Joint Committee on Cancer stages, with 80.2 % of stage I patients receiving surgery compared with 54.0 % of stage II patients, 36.8 % of stage III patients, and 28.5 % of stage IV patients (p < 0.001). Black patients with high socioeconomic status (SES) showed lower use of surgery (25.3 %) compared to low SES white (32.3 %) and low SES Hispanic patients (27.3 %) (p < 0.001). The highest surgical rates were noted in the West North Central region and lowest rates were observed in the New England and South Atlantic regions. Between 2009 and 2012, independent predictors of surgical treatment included young age, female gender, white or Hispanic race, high SES, private insurance, academic hospitals, hospitals in the West North Central region, residence more than 75 miles from the hospital, increasing comorbidities, stage I disease, and tonsil origin (all p < 0.05).
CONCLUSION: Since FDA approval of TORS in 2009, surgical rates have increased with multiple socioeconomic and regional factors affecting patient selection. This study provides a basis for further investigation into factors involved in decision making for OPC patients.

Entities:  

Mesh:

Year:  2015        PMID: 25893414     DOI: 10.1245/s10434-015-4560-x

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  13 in total

1.  [Advances in transoral robotic surgery].

Authors:  S Mattheis; B Kansy; P Haßkamp; L Holtmann; S Lang
Journal:  HNO       Date:  2015-11       Impact factor: 1.284

Review 2.  Treatment preferences in human papillomavirus-associated oropharyngeal cancer.

Authors:  Melina J Windon; Gypsyamber D'Souza; Carole Fakhry
Journal:  Future Oncol       Date:  2018-09-28       Impact factor: 3.404

3.  Racial disparities in the choice of definitive treatment for squamous cell carcinoma of the oral cavity.

Authors:  Carol M Lewis; Gaurav S Ajmani; Alexandra Kyrillos; Paul Chamberlain; Chi-Hsiung Wang; Cheryl C Nocon; Monica Peek; Mihir K Bhayani
Journal:  Head Neck       Date:  2018-06-26       Impact factor: 3.147

Review 4.  Postoperative Treatment of Oropharyngeal Cancer in the Era of Human Papillomavirus.

Authors:  Jessica L Geiger; Jamie A Ku
Journal:  Curr Treat Options Oncol       Date:  2019-02-15

5.  Treatment selection in oropharyngeal cancer: a surveillance, epidemiology, and end results (SEER) patterns of care analysis.

Authors:  Nitin A Pagedar; Catherine Chioreso; Jennifer A Schlichting; Charles F Lynch; Mary E Charlton
Journal:  Cancer Causes Control       Date:  2017-08-16       Impact factor: 2.506

6.  Increase in primary surgical treatment of T1 and T2 oropharyngeal squamous cell carcinoma and rates of adverse pathologic features: National Cancer Data Base.

Authors:  Jennifer R Cracchiolo; Shrujal S Baxi; Luc G Morris; Ian Ganly; Snehal G Patel; Marc A Cohen; Benjamin R Roman
Journal:  Cancer       Date:  2016-03-11       Impact factor: 6.860

7.  Predictors of gastrostomy tube dependence in surgically managed oropharyngeal squamous cell carcinoma.

Authors:  Vivek R Varma; Antoine Eskander; Stephen Y Kang; Bhavna Kumar; Nicole V Brown; Songzhu Zhao; Guy Brock; Amit Agrawal; Ricardo L Carrau; Matthew O Old; Enver Ozer; James W Rocco; David E Schuller; Peter T Dziegielewski; Michael J Cipolla; Theodoros N Teknos
Journal:  Laryngoscope       Date:  2018-09-08       Impact factor: 3.325

8.  Dysphagia profiles after primary transoral robotic surgery or radiation for oropharyngeal cancer: A registry analysis.

Authors:  Carly E A Barbon; Christopher M K L Yao; Clare P Alvarez; Ryan P Goepfert; Clifton D Fuller; Stephen Y Lai; Neil D Gross; Katherine A Hutcheson
Journal:  Head Neck       Date:  2021-06-03       Impact factor: 3.821

9.  Phototheranostic Porphyrin Nanoparticles Enable Visualization and Targeted Treatment of Head and Neck Cancer in Clinically Relevant Models.

Authors:  Nidal Muhanna; Cheng S Jin; Elizabeth Huynh; Harley Chan; Yi Qiu; Wenlei Jiang; Liyang Cui; Laura Burgess; Margarete K Akens; Juan Chen; Jonathan C Irish; Gang Zheng
Journal:  Theranostics       Date:  2015-10-18       Impact factor: 11.556

10.  Systemic inflammation is an independent predictive marker of clinical outcomes in mucosal squamous cell carcinoma of the head and neck in oropharyngeal and non-oropharyngeal patients.

Authors:  Kellie A Charles; Benjamin D W Harris; Carol R Haddad; Stephen J Clarke; Alex Guminski; Mark Stevens; Tristan Dodds; Anthony J Gill; Michael Back; David Veivers; Thomas Eade
Journal:  BMC Cancer       Date:  2016-02-18       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.